Every year more people across the EU are diagnosed with life-threatening conditions which can only be treated with plasma-derived medicines.
The revision of the European Union Blood, Tissues and Cells (BTC) Legislation brings an opportunity to strengthen its legal framework to encourage new approaches that will increase the collection of plasma across Europe.
In the coming decade, it is expected that more European patients will need access to plasma-derived medicines.
Remarks on establishing a reliable supply of therapies, the urgent need to increase plasma collection across the EU, and the impact of the COVID-19 on the plasma donation system (as of October 2020), presented at the Global Plasma Summit.
